Guggenheim Initiates Coverage on Sienna Biopharmaceuticals (SNNA)

Investment analysts at Guggenheim started coverage on shares of Sienna Biopharmaceuticals (NASDAQ:SNNA) in a note issued to investors on Tuesday. The brokerage set a “neutral” rating and a $21.00 price target on the stock. Guggenheim’s target price points to a potential upside of 4.17% from the stock’s previous close.

Several other equities analysts also recently weighed in on the company. Cowen assumed coverage on Sienna Biopharmaceuticals in a research report on Monday, August 21st. They issued an “outperform” rating and a $50.00 target price on the stock. J P Morgan Chase & Co assumed coverage on Sienna Biopharmaceuticals in a research report on Monday, August 21st. They issued an “overweight” rating and a $28.00 target price on the stock. Finally, BMO Capital Markets assumed coverage on Sienna Biopharmaceuticals in a research report on Monday, August 21st. They issued an “outperform” rating and a $30.00 target price on the stock.

Shares of Sienna Biopharmaceuticals (SNNA) opened at $20.16 on Tuesday. Sienna Biopharmaceuticals has a 1-year low of $15.22 and a 1-year high of $29.25.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last issued its quarterly earnings data on Thursday, September 7th. The company reported ($6.50) EPS for the quarter, missing the consensus estimate of ($0.68) by ($5.82). sell-side analysts forecast that Sienna Biopharmaceuticals will post -2.1 EPS for the current fiscal year.

In other news, Director Dennis M. Fenton bought 1,250 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were acquired at an average price of $22.96 per share, for a total transaction of $28,700.00. Following the completion of the transaction, the director now directly owns 1,250 shares in the company, valued at approximately $28,700. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SNNA. California State Teachers Retirement System purchased a new position in Sienna Biopharmaceuticals during the third quarter worth approximately $182,000. Bank of New York Mellon Corp purchased a new position in Sienna Biopharmaceuticals during the third quarter worth approximately $274,000. Citadel Advisors LLC purchased a new position in Sienna Biopharmaceuticals during the third quarter worth approximately $440,000. Alyeska Investment Group L.P. purchased a new position in Sienna Biopharmaceuticals during the third quarter worth approximately $1,133,000. Finally, TimesSquare Capital Management LLC purchased a new position in Sienna Biopharmaceuticals during the third quarter worth approximately $8,571,000. Institutional investors and hedge funds own 39.29% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Guggenheim Initiates Coverage on Sienna Biopharmaceuticals (SNNA)” was first published by Zolmax and is the property of of Zolmax. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://zolmax.com/investing/guggenheim-initiates-coverage-on-sienna-biopharmaceuticals-snna/1829287.html.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.

Receive News & Ratings for Sienna Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barclays Analysts Give Munchener Ruckvers  a €205.00 Price Target
Barclays Analysts Give Munchener Ruckvers a €205.00 Price Target
Wells Fargo & Company Upgrades Sunesis Pharmaceuticals  to Outperform
Wells Fargo & Company Upgrades Sunesis Pharmaceuticals to Outperform
Arsanis  Now Covered by Piper Jaffray Companies
Arsanis Now Covered by Piper Jaffray Companies
SendGrid  Research Coverage Started at Stifel Nicolaus
SendGrid Research Coverage Started at Stifel Nicolaus
Capital Bank & Trust Co Has $30.77 Million Holdings in The AES Corporation
Capital Bank & Trust Co Has $30.77 Million Holdings in The AES Corporation
Critical Analysis: Intelsat  & Meru Networks
Critical Analysis: Intelsat & Meru Networks


Leave a Reply

 
© 2006-2017 Zolmax.